(KE) Kimball Electronics - Overview
Stock: Electronics, Assemblies, Contract-Manufacturing, Medical-Disposables
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 102% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 26.75 |
| Character TTM | |
|---|---|
| Beta | 1.317 |
| Beta Downside | 1.504 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.50% |
| CAGR/Max DD | 0.01 |
Description: KE Kimball Electronics December 27, 2025
Kimball Electronics (NASDAQ:KE) is a contract manufacturing organization that delivers end-to-end electronics solutions-including PCB assembly, precision-molded plastics, cold-chain logistics, and product sterilization-for automotive, medical, and industrial customers. The firm also provides design-for-manufacturing, rapid prototyping, reliability testing, and aftermarket lifecycle services across a global footprint that spans the United States, China, Mexico, Europe, and Southeast Asia.
In its most recent fiscal year (2023), Kimball reported approximately $1.5 billion in revenue with an operating margin near 5%, and a backlog of roughly $500 million, indicating a moderate but stable order pipeline. The company’s earnings per share (EPS) trended upward year-over-year, driven largely by higher utilization rates in its automotive and medical segments.
Key macro-level drivers for Kimball include the accelerating shift toward electric-vehicle (EV) platforms, which is boosting demand for high-precision electronic modules, and the continued outsourcing of medical-device production to specialist manufacturers to meet stringent regulatory and sterilization requirements. Additionally, the sector benefits from a resilient US manufacturing PMI (averaging 53-55 in 2023) and from supply-chain diversification trends that favor multi-regional production footprints.
For a deeper quantitative assessment of KE’s valuation dynamics, you may find it useful to explore the analytics available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 24.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -1.34 > 1.0 |
| NWC/Revenue: 17.80% < 20% (prev 25.05%; Δ -7.26% < -1%) |
| CFO/TA 0.11 > 3% & CFO 123.9m > Net Income 24.1m |
| Net Debt (76.0m) to EBITDA (85.1m): 0.89 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.8m) vs 12m ago -0.58% < -2% |
| Gross Margin: 7.80% > 18% (prev 0.07%; Δ 772.9% > 0.5%) |
| Asset Turnover: 135.5% > 50% (prev 147.7%; Δ -12.19% > 0%) |
| Interest Coverage Ratio: 4.31 > 6 (EBITDA TTM 85.1m / Interest Expense TTM 11.1m) |
Altman Z'' 4.85
| A: 0.24 (Total Current Assets 573.5m - Total Current Liabilities 313.4m) / Total Assets 1.08b |
| B: 0.32 (Retained Earnings 347.3m / Total Assets 1.08b) |
| C: 0.04 (EBIT TTM 48.0m / Avg Total Assets 1.08b) |
| D: 1.84 (Book Value of Equity 927.9m / Total Liabilities 504.3m) |
| Altman-Z'' Score: 4.85 = AA |
Beneish M -2.36
| DSRI: 1.00 (Receivables 293.5m/317.1m, Revenue 1.46b/1.59b) |
| GMI: 0.95 (GM 7.80% / 7.39%) |
| AQI: 2.45 (AQ_t 0.22 / AQ_t-1 0.09) |
| SGI: 0.92 (Revenue 1.46b / 1.59b) |
| TATA: -0.09 (NI 24.1m - CFO 123.9m) / TA 1.08b) |
| Beneish M-Score: -2.36 (Cap -4..+1) = BBB |
What is the price of KE shares?
Over the past week, the price has changed by -12.98%, over one month by -11.87%, over three months by -6.64% and over the past year by +51.01%.
Is KE a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33 | 25.5% |
| Analysts Target Price | 33 | 25.5% |
| ValueRay Target Price | 28.6 | 8.7% |
KE Fundamental Data Overview February 07, 2026
P/S = 0.3928
P/B = 1.2917
Revenue TTM = 1.46b USD
EBIT TTM = 48.0m USD
EBITDA TTM = 85.1m USD
Long Term Debt = 129.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 24.1m USD (from shortTermDebt, last quarter)
Debt = 153.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 76.0m USD (from netDebt column, last quarter)
Enterprise Value = 650.3m USD (574.3m + Debt 153.8m - CCE 77.9m)
Interest Coverage Ratio = 4.31 (Ebit TTM 48.0m / Interest Expense TTM 11.1m)
EV/FCF = 5.90x (Enterprise Value 650.3m / FCF TTM 110.3m)
FCF Yield = 16.96% (FCF TTM 110.3m / Enterprise Value 650.3m)
FCF Margin = 7.54% (FCF TTM 110.3m / Revenue TTM 1.46b)
Net Margin = 1.65% (Net Income TTM 24.1m / Revenue TTM 1.46b)
Gross Margin = 7.80% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = 8.17% (prev 7.89%)
Tobins Q-Ratio = 0.60 (Enterprise Value 650.3m / Total Assets 1.08b)
Interest Expense / Debt = 1.36% (Interest Expense 2.10m / Debt 153.8m)
Taxrate = 47.92% (3.35m / 6.98m)
NOPAT = 25.0m (EBIT 48.0m * (1 - 47.92%))
Current Ratio = 1.83 (Total Current Assets 573.5m / Total Current Liabilities 313.4m)
Debt / Equity = 0.27 (Debt 153.8m / totalStockholderEquity, last quarter 579.2m)
Debt / EBITDA = 0.89 (Net Debt 76.0m / EBITDA 85.1m)
Debt / FCF = 0.69 (Net Debt 76.0m / FCF TTM 110.3m)
Total Stockholder Equity = 568.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.24% (Net Income 24.1m / Total Assets 1.08b)
RoE = 4.24% (Net Income TTM 24.1m / Total Stockholder Equity 568.6m)
RoCE = 6.88% (EBIT 48.0m / Capital Employed (Equity 568.6m + L.T.Debt 129.7m))
RoIC = 3.48% (NOPAT 25.0m / Invested Capital 719.3m)
WACC = 8.64% (E(574.3m)/V(728.1m) * Re(10.77%) + D(153.8m)/V(728.1m) * Rd(1.36%) * (1-Tc(0.48)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.77%
[DCF Debug] Terminal Value 67.34% ; FCFF base≈115.7m ; Y1≈75.9m ; Y5≈34.6m
Fair Price DCF = 21.89 (EV 608.8m - Net Debt 76.0m = Equity 532.8m / Shares 24.3m; r=8.64% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.87 | EPS CAGR: -16.07% | SUE: 0.17 | # QB: 0
Revenue Correlation: -45.57 | Revenue CAGR: -1.99% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=+0.014 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-06-30): EPS=1.36 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+21.4% | Growth Revenue=-5.1%
EPS next Year (2027-06-30): EPS=1.45 | Chg30d=-0.052 | Revisions Net=+2 | Growth EPS=+6.9% | Growth Revenue=+4.5%